Iboga in the United States · WA
Iboga and ibogaine in Washington
Washington funds University of Washington ibogaine research: $250,000 in the 2024 supplemental budget and a $10,000 randomized cohort study proviso in the 2025-27 budget, kept in the 2026 supplemental.
Status
Research funded
$260,000
State research funding
1
Bills tracked
October 26, 2026
Last checked
Where Washington stands
The 2024 supplemental budget provided $250,000 to the UW Center for Novel Therapeutics in Addiction Psychiatry for an initial ibogaine-assisted therapy study, billed as the first state-funded ibogaine research. SB 5204 (Salomon, Trudeau, Nobles) proposed a three-year UW study and was heard 2025-02-06. The enacted 2025-27 operating budget (ESSB 5167, Chapter 424, Laws of 2025) then provided $10,000 for a UW prospective, randomized cohort study, running 2025-07-01 to 2027-06-30, comparing ibogaine-assisted therapy at a licensed clinic in North America with standard U.S. opioid use disorder treatment. The governor's partial veto left that proviso intact, and the 2026 supplemental budget (ESSB 5998) carried it forward.
The state has appropriated money for ibogaine research or trials.
Funding: $260,000. $250,000 from the opioid abatement settlement account in the 2024 supplemental budget for the UW Center for Novel Therapeutics in Addiction Psychiatry's initial ibogaine-assisted therapy study, plus $10,000 from the workforce education investment account in the 2025-27 budget (ESSB 5167 Sec. 606(62), kept in the 2026 supplemental ESSB 5998) for a UW randomized cohort study of ibogaine-assisted therapy for opioid use disorder running to 2027-06-30.
Timeline
2026 supplemental budget keeps the ibogaine study proviso
The 2026 supplemental operating budget (ESSB 5998, Chapter 268, Laws of 2026, effective 2026-04-01) amends the University of Washington section and carries the $10,000 ibogaine cohort-study proviso forward unchanged; that section was outside the governor's partial-veto items.
Source: Washington State Legislature (ESSB 5998 session law)
News coverage of Salomon ibogaine push
The Stranger reported Sen. Salomon wants to bring ibogaine therapy to Washington.
Source: The Stranger
2025-27 budget funds a UW ibogaine cohort study
The enacted 2025-27 operating budget (ESSB 5167, Chapter 424, Laws of 2025) provides $10,000 from the workforce education investment account for the University of Washington to run a prospective, randomized cohort study from 2025-07-01 to 2027-06-30 comparing ibogaine-assisted therapy at a licensed clinic in North America, followed by structured therapeutic support, with standard U.S. opioid use disorder treatment. The university may add private philanthropic funding. The governor's partial veto of the UW section struck subsection 606(64) and left the ibogaine subsection 606(62) in law.
Source: Washington State Legislature (ESSB 5167 session law)
SB 5204 heard in Health & Long-Term Care
Bill would create a three-year UW study of ibogaine-assisted therapy versus treatment as usual for adults with opioid use disorder, at a licensed clinic in Mexico.
Source: WA Senate Bill Report
Senate budget proposes ibogaine study funding
Sen. Salomon's office announced the Senate budget would fund a first-in-the-nation ibogaine study for opioid use disorder; later sources cite $250,000 in the 2024 supplemental budget.
Bills
| Bill | Title | Status |
|---|---|---|
| SB 5204 | Studying outcomes of ibogaine-assisted therapy to treat adults with opioid use disorder | Heard 2025-02-06; did not pass as a standalone bill. A UW ibogaine cohort study was funded instead as a budget proviso in ESSB 5167 (Chapter 424, Laws of 2025, Sec. 606(62)), retained in the 2026 supplemental ESSB 5998 |
Who is involved
- University of Washington Center for Novel Therapeutics in Addiction Psychiatry (NTAP)
Recipient of the 2024 state ibogaine study funding.
Universities and research centers
- Sen. Jesse Salomon (official page)
Lead sponsor of SB 5204 and the ibogaine study funding.
Legislators and legislative offices
For Washington residents: a whole root ceremony on Kauaʻi
Vital Kauaʻi is a legally established church on Kauaʻi’s North Shore. Members from Washington join a thirteen-week journey: six weeks of preparation from home, one week on the island with two held nights with the whole root in ceremony, and six weeks of integration after. Guides, a medical provider, somatic practitioners and integration coaches walk with each member through all of it.
Preparation, from Washington
A medical consultation and health review, somatic and nervous-system preparation, and weekly guidance through the member portal. All of it happens from home, on Zoom, before travel.
Ceremony, on Kauaʻi
Two nights with the whole root in nature, one-on-one or in a container of up to three, with experienced guides and the medical provider present overnight. An EKG on-island comes first.
Integration, back in Washington
Six weekly one-on-one calls with an integration coach, plus somatic sessions, so what the root shows you becomes how you live, lead and create at home.
Book a discovery callThirty minutes on Zoom. We meet you, and you share what is calling you.
From Washington’s cities
Flights, time difference and the same path, for each metro.
In the news, video and podcasts
News, videos and podcasts that name Washington appear here as Iboga Worldwide gathers it, daily.
Every state
How this tracker is kept
- Each state is checked against legislature records, agency releases and published reporting, and carries the date it was last checked. Every development links to its source.
- “No known activity” means the state was checked on the date shown and no ibogaine-specific law, bill, funding or task force was found.
- The directory lists organizations and public offices with their own websites. Listing points readers to them and does not endorse them.
- This tracker is offered for education and does not constitute legal or medical advice. Ibogaine and iboga remain Schedule I substances under federal law. See the medical disclaimer.
- To share a development or request a correction, write to aloha@vitalkauai.com. For daily coverage, see Iboga Worldwide.